Combination therapy for advanced stomach cancer
Part of Cancer clinical trials.
This study tests a combination of two medications (Sac-TMT and fruquintinib) as a second-line treatment for advanced stomach cancer. The goal is to see if this combination can help shrink tumors or slow the cancer's growth after a first treatment has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach or gastroesophageal junction cancer that has spread or cannot be surgically removed.
- You must have tried one standard first-line treatment that no longer controls the cancer, or cancer returned within 6 months of finishing adjuvant therapy.
- You must be generally active and able to care for yourself (ECOG score 0 or 1).
- Your organs (blood, liver, kidneys) must be working well enough, without needing recent transfusions or growth factor shots.
- You must be able to swallow pills and have no active ulcers, bleeding, or perforation in your stomach or intestines.
- If you could become pregnant or father a child, you must agree to use effective contraception during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new combination of two drugs (fruquintinib and sintilimab) plus focused radiation for people with advanced stomach or gastroesophageal junction cancer that has progressed after earlier treatments. The goal is to see if this approach can help control the cancer.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.